Every assertion on this site traces back to published, peer-reviewed research. This library presents the studies directly — with plain-English summaries alongside the original citations, so you can read both the interpretation and the source.
Studies are selected for clinical significance, methodological quality, and relevance to chelation therapy as used in practice. Plain-English summaries are our interpretation — they are not the authors' words. Where a finding is preliminary or contested, this is noted. New entries are released every one to two weeks — subscribe below to be notified.
TACT2 was designed as a follow-up to the original TACT trial. In TACT, investigators reported an 18% relative reduction in cardiovascular events in the overall study population of 1,708 patients with prior myocardial infarction. A prespecified subgroup analysis suggested a substantially larger benefit in participants with diabetes, which led researchers to test that finding directly in TACT2.
Between 2016 and 2023, TACT2 enrolled 1,000 patients with diabetes and prior myocardial infarction at 88 sites in the United States and Canada. Participants were randomized to receive edetate disodium-based chelation infusions or placebo in a double-masked trial.
TACT2 confirmed that the chelation regimen substantially lowered blood lead levels. However, it did not show a significant reduction in the primary cardiovascular composite endpoint compared with placebo. In other words, TACT2 did not replicate the cardiovascular benefit suggested by the diabetes subgroup in the original TACT trial.
TACT2 is an important trial because it tested the population thought most likely to benefit based on TACT. Its findings make the cardiovascular evidence for EDTA chelation more uncertain — the original trial suggested benefit, while the dedicated replication trial in diabetic post-MI patients was neutral on clinical outcomes, despite clear blood lead reduction.
Bottom line — TACT2 confirmed that edetate disodium–based chelation lowers blood lead levels, but it did not reproduce the cardiovascular event reduction suggested in the diabetes subgroup of the original TACT trial. Taken together, TACT and TACT2 leave the cardiovascular evidence mixed rather than confirmatory.
View on PubMed →This study extended the kidney disease research further, following 116 patients with non-diabetic chronic kidney disease over a four-year clinical trial. Patients were randomised to receive EDTA chelation or placebo, with treatment administered for three months initially and then repeated as needed based on lead mobilisation testing. Kidney function was tracked throughout using serum creatinine as the primary marker.
Over four years, EDTA chelation therapy significantly slowed progression of kidney disease even in patients with normal blood lead levels at baseline. This builds on the NEJM finding above, confirming the effect over a longer timeframe and reinforcing that subclinical lead accumulation — not just overt poisoning — is clinically significant.
Bottom line — Repeated EDTA chelation slowed kidney disease progression in non-diabetic CKD patients over four years, even in patients whose blood lead levels were within the normal range at baseline. The findings reinforce that subclinical lead burden — not just overt poisoning — is clinically meaningful, and that addressing it can measurably affect long-term outcomes.
View on PubMed →Published in the New England Journal of Medicine — the highest-impact medical journal in the world — this study examined 202 patients with chronic kidney disease who had no known history of lead exposure. Over 24 months of monitoring, 64 were found to have elevated body lead levels despite no occupational or obvious environmental exposure. These patients were then randomised to receive EDTA chelation or placebo for 27 months.
Kidney function improved significantly in the chelation group over 27 months. Critically, the researchers concluded that even low-level environmental lead exposure — the kind most adults have without realising — accelerates kidney disease progression. EDTA chelation slowed this progression measurably.
Bottom line — In patients with chronic kidney disease and no known occupational lead exposure, EDTA chelation slowed the rate of kidney function decline over 27 months. The clinical takeaway is that low-level environmental lead exposure — the kind most adults carry — can accelerate kidney disease, and that chelation can measurably modify that trajectory in affected patients.
View on PubMed →This report examined the four factorial treatment groups from the original TACT trial — comparing EDTA alone, vitamins alone, EDTA plus vitamins, and double placebo. The 1,708-participant dataset allowed a direct head-to-head comparison of all combinations, including a pre-specified analysis in diabetic patients.
The combination of EDTA chelation plus high-dose oral vitamins and minerals reduced cardiovascular events to an extent that was both statistically significant and clinically relevant — with a hazard ratio of 0.74 overall and 0.49 in diabetic patients, representing a 51% relative risk reduction in that subgroup.
Bottom line — In the TACT trial, the combination of EDTA chelation plus high-dose oral vitamins and minerals reduced cardiovascular events more than either intervention alone — with the strongest effect (51% relative risk reduction) in diabetic patients. This finding shaped the design of TACT2; subsequent results from TACT2 did not confirm the cardiovascular benefit in diabetic post-MI patients, leaving the combined-therapy question open.
View on PubMed →This review examines the intersection of heavy metal exposure, chronic kidney disease, and cardiovascular disease. It summarizes clinical evidence showing that even low-level environmental lead exposure accelerates kidney function decline, and that weekly low-dose calcium EDTA chelation slowed that progression in both diabetic and non-diabetic patients with chronic kidney disease.
In patients with chronic kidney disease and elevated body lead burden, weekly low-dose calcium EDTA chelation slowed the rate of renal function decline — in both diabetic and non-diabetic patients — suggesting a protective role for chelation beyond acute toxicity treatment.
Bottom line — This review consolidates the evidence linking environmental heavy metal exposure to chronic kidney and cardiovascular disease, and summarizes the case for chelation as an adjunctive therapy in affected populations. The strongest signals appear in patients with both elevated body lead burden and pre-existing kidney or cardiovascular disease — supporting a role for chelation beyond acute poisoning treatment.
View on PubMed →This retrospective analysis reviewed 470 patients who had received EDTA chelation treatment for moderate to severe arteriosclerosis. Before treatment, 92 of these patients had already been referred for surgical evaluation due to the severity of their condition. The researchers tracked objective cardiovascular outcomes before and after chelation.
80% of patients showed objective improvement in cardiovascular condition. Of the 92 patients previously referred for surgery, only 10 ultimately required it after EDTA treatment — suggesting chelation may reduce the need for surgical intervention in a meaningful proportion of patients.
Bottom line — In this retrospective cohort of 470 patients with moderate to severe arteriosclerosis, 80% showed objective cardiovascular improvement following EDTA chelation, and only 10 of the 92 patients previously referred for surgery ultimately required it. The study is observational rather than randomized — its strength is the size of the cohort and the objective outcome measures, not causal proof. It is best read as a clinical signal that helped motivate later randomized trials.
VIEW ON RESEARCHGATE →This paper analysed a pre-specified subgroup of the TACT trial — patients with diabetes mellitus who had previously suffered a heart attack. Diabetes dramatically increases the risk of atherosclerosis and cardiovascular events, making this population particularly important. The subgroup analysis was published separately because the findings were substantially stronger than the overall TACT result.
Diabetic patients receiving EDTA chelation had a 40–59% reduction in cardiovascular events compared to placebo — a markedly stronger effect than seen in the non-diabetic population. The researchers proposed that EDTA's ability to chelate metal ions that catalyse damaging glycation end-products may explain the amplified benefit in this group.
Bottom line — In a pre-specified subgroup analysis of TACT, diabetic post-MI patients receiving EDTA chelation showed a 40-59% reduction in cardiovascular events compared to placebo — substantially larger than the overall TACT effect. This finding generated the hypothesis tested directly in TACT2 (Study 008), which did not confirm the benefit in a dedicated diabetic cohort. The diabetic subgroup remains the most-studied population for EDTA cardiovascular research, with mixed results across the two major trials.
View on AHA | ASA →87% of all studied patients demonstrated significant clinical improvement by objective measurement. The meta-analysis revealed a statistical correlation coefficient of 0.88 between EDTA therapy and improved cardiovascular function — indicating a high positive relationship across all included studies.
87% of all studied patients demonstrated significant clinical improvement by objective measurement. The meta-analysis revealed a statistical correlation coefficient of 0.88 between EDTA therapy and improved cardiovascular function.
Bottom line — This early meta-analysis pooled cardiovascular outcomes across 19 studies and 22,765 patients, reporting that 87% showed clinical improvement following EDTA chelation, with a strong statistical correlation (r = 0.88) between treatment and improvement. The meta-analysis predates modern RCT standards and consists primarily of observational and pre-RCT data — a useful historical signal that motivated the NIH-funded TACT trial, but not equivalent in rigor to the randomized evidence that followed.
View PDF →This is the most significant study ever conducted on EDTA chelation therapy. Funded by the NIH and published in the Journal of the American Medical Association — the most widely read medical journal in the world — the Trial to Assess Chelation Therapy (TACT) enrolled 1,708 patients across 134 hospitals in the US and Canada. All participants had previously suffered a heart attack. Half received 40 infusions of IV EDTA; the other half received a placebo infusion. The primary endpoint was a composite of death, heart attack, stroke, coronary revascularisation, and hospitalisation for angina.
Patients in the EDTA group had an 18% reduction in the composite primary endpoint compared to placebo. The researchers concluded the results provide sufficient evidence to "support the routine use of chelation therapy for treatment of patients who have had a myocardial infarction" due to atherosclerosis.
Bottom line — TACT remains the largest randomized trial of EDTA chelation for cardiovascular disease, demonstrating an 18% reduction in the composite cardiovascular endpoint in post-MI patients overall, with stronger effects in the diabetic subgroup. The follow-up TACT2 trial (Study 008), designed specifically to confirm the diabetic finding, did not reproduce that benefit. The TACT/TACT2 picture is now mixed: real reductions in blood lead were achieved in both, but the cardiovascular outcomes were positive in TACT and neutral in TACT2.
View on PubMed →